Render Target: STATIC
Render Timestamp: 2024-11-07T10:47:36.699Z
Commit: 3c1f305a63297e594ac8d7bb5424007d592d68be
XML generation date: 2024-08-01 15:28:04.816
Product last modified at: 2024-05-30T07:02:22.244Z
1% for the planet logo
PDP - Template Name: Polyclonal Antibody
PDP - Template ID: *******59c6464

TRBC1/TCRβ constant region 1 Antibody #77046

Filter:
  • WB

    Supporting Data

    REACTIVITY H
    SENSITIVITY Endogenous
    MW (kDa) 30-40
    SOURCE Rabbit
    Application Key:
    • WB-Western Blotting 
    Species Cross-Reactivity Key:
    • H-Human 

    Product Information

    Product Usage Information

    Application Dilution
    Western Blotting 1:1000

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Store at –20°C. Do not aliquot the antibody.

    Protocol

    Specificity / Sensitivity

    TRBC1/TCRβ constant region 1 Antibody recognizes endogenous levels of total TRBC1/TCRβ constant region 1 protein. This antibody does not cross-react with TRBC2/TCRβ constant region 2 protein.

    Species Reactivity:

    Human

    Source / Purification

    Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues near the amino terminus of human TRBC1/TCRβ constant region 1 protein. Antibodies are purified by peptide affinity chromatography.

    Background

    The αβ T Cell Receptor (TCR) is a heterodimer composed of an alpha chain and a beta chain expressed on the surface of T cells (1,2). It detects peptide antigen presented by major histocompatibility complex (MHC) molecules (1,2). Detection of cognate antigen leads to activation of the TCR signaling pathway through the CD3 signaling chains that associate with the TCR (1). The TCR chains are made up of a constant region and variable regions that get rearranged during T cell development in the thymus (3). There are two TCRβ constant genes, TRBC1 and TRBC2 (3). A population of normal T cells is polyclonal and contains a mix of TRBC1- and TRBC2-expressing T cells, while T cell malignancies are monoclonal and all express the same TCR which either contains TRBC1 or TRBC2 (4). Therefore, it is possible that T cell malignancies could be identified and targeted with reagents or therapies that can distinguish between TRBC1 and TRBC2 (4).
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.